JP2009536652A5 - - Google Patents

Download PDF

Info

Publication number
JP2009536652A5
JP2009536652A5 JP2009509821A JP2009509821A JP2009536652A5 JP 2009536652 A5 JP2009536652 A5 JP 2009536652A5 JP 2009509821 A JP2009509821 A JP 2009509821A JP 2009509821 A JP2009509821 A JP 2009509821A JP 2009536652 A5 JP2009536652 A5 JP 2009536652A5
Authority
JP
Japan
Prior art keywords
treatment
solvate
hydrate
mammal
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009509821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536652A (ja
JP5273038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011136 external-priority patent/WO2007133562A2/en
Publication of JP2009536652A publication Critical patent/JP2009536652A/ja
Publication of JP2009536652A5 publication Critical patent/JP2009536652A5/ja
Application granted granted Critical
Publication of JP5273038B2 publication Critical patent/JP5273038B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009509821A 2006-05-08 2007-05-08 単環式ヘテロアリール化合物 Expired - Fee Related JP5273038B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79847206P 2006-05-08 2006-05-08
US60/798,472 2006-05-08
US83319106P 2006-07-25 2006-07-25
US60/833,191 2006-07-25
US92068707P 2007-03-29 2007-03-29
US60/920,687 2007-03-29
PCT/US2007/011136 WO2007133562A2 (en) 2006-05-08 2007-05-08 Monocyclic heteroaryl compounds

Publications (3)

Publication Number Publication Date
JP2009536652A JP2009536652A (ja) 2009-10-15
JP2009536652A5 true JP2009536652A5 (enExample) 2010-06-17
JP5273038B2 JP5273038B2 (ja) 2013-08-28

Family

ID=38694440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009509821A Expired - Fee Related JP5273038B2 (ja) 2006-05-08 2007-05-08 単環式ヘテロアリール化合物

Country Status (13)

Country Link
US (3) US8278307B2 (enExample)
EP (1) EP2024366B1 (enExample)
JP (1) JP5273038B2 (enExample)
KR (1) KR101441365B1 (enExample)
CN (1) CN103467385B (enExample)
AU (1) AU2007249926B8 (enExample)
BR (1) BRPI0710331A2 (enExample)
CA (1) CA2650273C (enExample)
EA (1) EA200870515A1 (enExample)
ES (1) ES2555515T3 (enExample)
IL (1) IL194678A (enExample)
MX (1) MX2008014290A (enExample)
WO (1) WO2007133562A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007021937A2 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
EP2495016B1 (en) 2005-12-23 2019-10-16 Ariad Pharmaceuticals, Inc. Bicyclic Heteroaryl Compounds
MX2008014289A (es) * 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos acetilenicos.
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
CA2743449C (en) 2008-11-12 2016-10-18 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
WO2012127030A1 (en) * 2011-03-23 2012-09-27 Proteosys Ag Arylpiperazines as neuroprotective agents
WO2013170770A1 (zh) * 2012-05-16 2013-11-21 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
CN103848829B (zh) 2012-11-28 2017-04-12 南京圣和药业股份有限公司 杂芳基炔烃化合物及其应用
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20140343282A1 (en) 2013-05-16 2014-11-20 Apicore, Llc Processes for making ponatinib and intermediates thereof
GB2522226A (en) * 2014-01-17 2015-07-22 Agency Science Tech & Res Heteroaryl alkyne derivatives and uses thereof
CN105272930B (zh) 2014-07-17 2018-07-13 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
MA51878A (fr) * 2016-12-15 2020-12-30 Ariad Pharma Inc Composés d'aminothiazole en tant qu'inhibiteurs de c-kit

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
CA2425097A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US20040110802A1 (en) * 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
DE602004018193D1 (de) 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
JP2007517006A (ja) 2003-12-24 2007-06-28 アストラゼネカ アクチボラグ Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン
BRPI0508790A (pt) 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007021937A2 (en) * 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
EP2495016B1 (en) * 2005-12-23 2019-10-16 Ariad Pharmaceuticals, Inc. Bicyclic Heteroaryl Compounds
CN101490053B (zh) * 2006-05-08 2013-09-11 阿里亚德医药股份有限公司 单环杂芳基化合物
MX2008014289A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos acetilenicos.

Similar Documents

Publication Publication Date Title
JP2009536652A5 (enExample)
FIC20240039I1 (fi) Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I2 (nl) crisaborole, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NO2023047I1 (no) Cedazuridine, or a pharmaceutically acceptable salt thereof
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL301321I2 (nl) Delgocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat daarvan
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301057I1 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301021I1 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
JP2009524695A5 (enExample)
NL301042I1 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301004I2 (nl) Dacomitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
JP2012107057A5 (enExample)
JP2009502793A5 (enExample)
JP2011006431A5 (enExample)
JP2009545527A5 (enExample)
JP2010500116A5 (enExample)
NL300871I2 (nl) ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
JP2006213929A5 (enExample)
JP2008501714A5 (enExample)
JP2010505891A5 (enExample)
JP2013014622A5 (enExample)
JP2011505522A5 (enExample)